Key facts
- Notable investors include Render Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Mandos Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Mandos Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mandos Health
Developer of a biopharmaceutical drug intended to help patients who are affected with Niemann-Pick Type C1 disease. The company specializes in developing the Adrabetadex drug while collaborating with various partners, clinics, and organizations that are developing drugs for NPC1 diseases, enabling patients to access diagnostic and treatment options for NPC1 disease.
- Sector
- Healthcare
- HQ
- Thousand Oaks, CA, United States
- Founded
- 2024
- Website
- mandoshealth.com/
- Ownership
- Privately Held (backing)
Mandos Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mandos Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mandos Health in its N-PORT filings yet. We sweep new filings monthly.